Stockreport

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen, Inc.  (SRZN) 
PDF Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Recept [Read more]